UFP Technologies’ Medical Sales Surge 23.2% to $555.3m, Non-Medical Falls 11.5%
UFP Technologies grew revenue from $186m in 2020 to $602.8m in 2025, driven by a 23.2% medical segment increase to $555.3m and seven strategic acquisitions. Q1 2026 medical sales rose 5.9% to $143.4m, making up 93% of $154.2m total revenue though organic sales and operating income held flat.
1. Revenue Growth Trajectory
UFP Technologies increased total revenue from $186 million in 2020 to $602.8 million in 2025, achieving a five-year CAGR of 26%. The company completed seven acquisitions between 2024 and 2025 to bolster its medical segment while allowing non-medical operations to phase out.
2. Segment Performance in 2025
Medical sales rose 23.2% to $555.3 million in 2025, representing 92% of annual revenue, while non-medical revenue contracted 11.5% to $47.5 million. This shift highlights a deliberate strategy to concentrate on contract development and manufacturing for medical device OEMs.
3. Q1 2026 Results and Challenges
In Q1 2026, total revenue reached $154.2 million, with medical sales up 5.9% to $143.4 million and non-medical sales down 15% to $10.8 million. Despite the segment mix benefits, organic sales remained flat and adjusted operating income held at $25.8 million, indicating the next phase relies on execution of growth initiatives.
4. Profitability and Competitive Moat
Full-year 2025 operating income rose 14.1% to $92.3 million on an adjusted EBITDA of $121.1 million, reflecting a 14.8% average operating margin over five years. Custom-engineering relationships with medical OEMs and regulatory switching costs create a structural barrier to competition.